AU2001285886A1 - 2-guanidino-4-aryl-quinazoline - Google Patents

2-guanidino-4-aryl-quinazoline

Info

Publication number
AU2001285886A1
AU2001285886A1 AU2001285886A AU8588601A AU2001285886A1 AU 2001285886 A1 AU2001285886 A1 AU 2001285886A1 AU 2001285886 A AU2001285886 A AU 2001285886A AU 8588601 A AU8588601 A AU 8588601A AU 2001285886 A1 AU2001285886 A1 AU 2001285886A1
Authority
AU
Australia
Prior art keywords
guanidino
quinazoline
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285886A
Inventor
Dr. Norbert Beier
Rolf Gericke
Claudia Wilm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2001285886A1 publication Critical patent/AU2001285886A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AU2001285886A 2000-09-05 2001-08-13 2-guanidino-4-aryl-quinazoline Abandoned AU2001285886A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10043667 2000-09-05
DE10043667A DE10043667A1 (en) 2000-09-05 2000-09-05 2-guanidino-4-aryl-quinazolines
PCT/EP2001/009325 WO2002020496A1 (en) 2000-09-05 2001-08-13 2-guanidino-4-aryl-quinazoline

Publications (1)

Publication Number Publication Date
AU2001285886A1 true AU2001285886A1 (en) 2002-03-22

Family

ID=7655015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285886A Abandoned AU2001285886A1 (en) 2000-09-05 2001-08-13 2-guanidino-4-aryl-quinazoline

Country Status (16)

Country Link
US (1) US20040039001A1 (en)
EP (1) EP1315704A1 (en)
JP (1) JP2004508360A (en)
KR (1) KR20030062404A (en)
CN (1) CN1450996A (en)
AU (1) AU2001285886A1 (en)
BR (1) BR0113583A (en)
CA (1) CA2421222A1 (en)
CZ (1) CZ2003858A3 (en)
DE (1) DE10043667A1 (en)
MX (1) MXPA03001877A (en)
NO (1) NO20030999D0 (en)
PL (1) PL360391A1 (en)
RU (1) RU2003108861A (en)
WO (1) WO2002020496A1 (en)
ZA (1) ZA200302633B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163992A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-aryl-quinazolines
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10304374A1 (en) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic agent and medicament containing them
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010078449A2 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
CA2857302C (en) 2011-12-15 2020-08-25 Novartis Ag Use of inhibitors of the activity or function of pi3k
JP6392754B2 (en) 2012-08-21 2018-09-19 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting NHE-mediated reverse transport in the treatment of fluid retention or salt overload related diseases and gastrointestinal diseases
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2983667T1 (en) 2013-04-12 2019-09-30 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
JP2020505333A (en) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Inhibitors of NHE-mediated antiport
EP3565808A1 (en) 2017-01-09 2019-11-13 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
WO2019060051A1 (en) 2017-08-04 2019-03-28 Ardelyx, Inc. Glycyrrhetinic acid derivatives for treating hyperkalemia
TW202045523A (en) 2019-02-07 2020-12-16 美商阿德利克斯公司 Compounds and methods for treating hyperkalemia
CN114340631A (en) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 Combination for reducing serum phosphate in a patient

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131187A (en) * 1964-04-28 Certain z-guantoino-x-aryl-quinazolines
JPH11209350A (en) * 1998-01-26 1999-08-03 Eisai Co Ltd Nitrogen-containing heterocyclic derivative and medicine containing the same
DE10019062A1 (en) * 2000-04-18 2001-10-25 Merck Patent Gmbh Use of known and new 2-guanidino-4-aryl-quinazoline derivatives as NHE-3 inhibitors useful for the treatment of e.g. hypertension, thrombosis, cardiac ischemia, peripheral and CNS ischemia
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
DE10163992A1 (en) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-aryl-quinazolines

Also Published As

Publication number Publication date
RU2003108861A (en) 2004-09-20
MXPA03001877A (en) 2003-06-24
JP2004508360A (en) 2004-03-18
CZ2003858A3 (en) 2003-06-18
PL360391A1 (en) 2004-09-06
US20040039001A1 (en) 2004-02-26
ZA200302633B (en) 2004-09-08
DE10043667A1 (en) 2002-03-14
EP1315704A1 (en) 2003-06-04
CA2421222A1 (en) 2003-03-03
NO20030999D0 (en) 2003-03-04
CN1450996A (en) 2003-10-22
BR0113583A (en) 2003-07-15
KR20030062404A (en) 2003-07-25
WO2002020496A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
AU6419701A (en) Electropancreatography
AU2001262847A1 (en) Language-understanding
AU2001292739A1 (en) 1-oxorapamycins
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2002211620A1 (en) Autoanastomosis
AU2001258349A1 (en) Bisacylguanidine
AU2001296577A1 (en) Chlorophyllases
AU2001279754A1 (en) Indoloquinazolinones
AU2001285886A1 (en) 2-guanidino-4-aryl-quinazoline
AU2002211128A1 (en) Step-bike
AU2001290931A1 (en) Ski-snowboard
AU2001293852A1 (en) Sulfonylguanidine
AU2001258924A1 (en) Microsatellite-aflp
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2001291876A1 (en) Triazolo-epothilones
AU2002214354A1 (en) Neck-phone
AU2001262711A1 (en) Cytoprotectors
AU2001226668A1 (en) Crankshaft-starter-generator
AU2001260192A1 (en) Glycinamides
AU2001284173A1 (en) Calycins